NAVB logo

NAVB Long Term Liabilities

Annual Total Long Term Liabilities

$2.57 M
+$1.85 M+257.21%

December 31, 2022


Summary


Performance

NAVB Long Term Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNAVBbalance sheetmetrics:

Quarterly Long Term Liabilities

$700.30 K
-$200.00-0.03%

September 30, 2023


Summary


Performance

NAVB Quarterly Long Term Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNAVBbalance sheetmetrics:

Long Term Liabilities Formula

Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities

NAVB Long Term Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+257.2%-0.0%
3 y3 years+112.2%-0.0%
5 y5 years+287.1%-0.0%

NAVB Long Term Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+257.2%-73.7%at low
5 y5-yearat high+257.2%-84.7%at low
alltimeall time-95.9%+2473.0%-98.9%+600.3%

Navidea Biopharmaceuticals Long Term Liabilities History

DateAnnualQuarterly
Sep 2023
-
$700.30 K(-0.0%)
Jun 2023
-
$700.50 K(-73.7%)
Mar 2023
-
$2.66 M(+3.6%)
Dec 2022
$2.57 M(+257.2%)
$2.57 M(+3.2%)
Sep 2022
-
$2.49 M(+75.2%)
Jun 2022
-
$1.42 M(+75.3%)
Mar 2022
-
$811.30 K(+12.6%)
Dec 2021
$720.30 K(-27.7%)
$720.30 K(-1.2%)
Sep 2021
-
$729.00 K(-11.2%)
Jun 2021
-
$820.50 K(-9.8%)
Mar 2021
-
$909.40 K(-8.7%)
Dec 2020
$996.00 K(-17.8%)
$996.00 K(-7.8%)
Sep 2020
-
$1.08 M(-76.4%)
Jun 2020
-
$4.58 M(+277.7%)
Mar 2020
-
$1.21 M(+0.1%)
Dec 2019
$1.21 M(-1.6%)
$1.21 M(-9.4%)
Sep 2019
-
$1.34 M(-2.8%)
Jun 2019
-
$1.38 M(-5.0%)
Mar 2019
-
$1.45 M(+17.6%)
Dec 2018
$1.23 M(+85.4%)
$1.23 M(-1.6%)
Sep 2018
-
$1.25 M(+0.6%)
Jun 2018
-
$1.24 M(-7.0%)
Mar 2018
-
$1.34 M(+101.3%)
Dec 2017
$664.70 K(-93.5%)
$664.70 K(-5.9%)
Sep 2017
-
$706.30 K(+6.1%)
Jun 2017
-
$665.90 K(+14.1%)
Mar 2017
-
$583.80 K(-94.3%)
Dec 2016
$10.27 M(-83.6%)
$10.27 M(-8.3%)
Sep 2016
-
$11.20 M(+9.8%)
Jun 2016
-
$10.20 M(-17.4%)
Mar 2016
-
$12.35 M(-80.3%)
Dec 2015
$62.62 M(+92.2%)
$62.62 M(-0.7%)
Sep 2015
-
$63.07 M(+3.0%)
Jun 2015
-
$61.23 M(+83.4%)
Mar 2015
-
$33.39 M(+2.5%)
Dec 2014
$32.57 M(-1.4%)
$32.57 M(-19.7%)
Sep 2014
-
$40.57 M(-1.7%)
Jun 2014
-
$41.27 M(-1.3%)
Mar 2014
-
$41.80 M(+26.5%)
Dec 2013
$33.04 M(+359.6%)
$33.04 M(-5.0%)
Sep 2013
-
$34.77 M(+23.2%)
Jun 2013
-
$28.23 M(+168.9%)
Mar 2013
-
$10.50 M(+46.1%)
Dec 2012
$7.19 M(+7.1%)
$7.19 M(+87.0%)
Sep 2012
-
$3.84 M(-14.3%)
Jun 2012
-
$4.48 M(-12.1%)
Mar 2012
-
$5.10 M(-24.0%)
Dec 2011
$6.71 M(+140.9%)
$6.71 M(+837.1%)
Sep 2011
-
$716.40 K(-22.4%)
Jun 2011
-
$923.10 K(-3.6%)
Mar 2011
-
$957.90 K(-65.6%)
Dec 2010
$2.79 M(-83.1%)
$2.79 M(+39.3%)
Sep 2010
-
$2.00 M(-7.3%)
Jun 2010
-
$2.16 M(-87.2%)
Mar 2010
-
$16.88 M(+2.4%)
Dec 2009
$16.48 M(+59.7%)
$16.48 M(-3.7%)
Sep 2009
-
$17.12 M(-51.4%)
Jun 2009
-
$35.24 M(+61.0%)
Mar 2009
-
$21.89 M(+112.1%)
Dec 2008
$10.32 M
$10.32 M(+48.5%)
DateAnnualQuarterly
Sep 2008
-
$6.95 M(+1.0%)
Jun 2008
-
$6.88 M(+7.9%)
Mar 2008
-
$6.37 M(-27.9%)
Dec 2007
$8.84 M(+79.5%)
$8.84 M(+299.4%)
Sep 2007
-
$2.21 M(-37.4%)
Jun 2007
-
$3.54 M(+3.1%)
Mar 2007
-
$3.43 M(-30.4%)
Dec 2006
$4.92 M(-18.7%)
$4.92 M(-23.9%)
Sep 2006
-
$6.46 M(+2.3%)
Jun 2006
-
$6.32 M(+2.3%)
Mar 2006
-
$6.17 M(+2.0%)
Dec 2005
$6.05 M(-26.1%)
$6.05 M(+1.7%)
Sep 2005
-
$5.95 M(+1.6%)
Jun 2005
-
$5.86 M(+1.8%)
Mar 2005
-
$5.75 M(-29.8%)
Dec 2004
$8.19 M(+1300.1%)
$8.19 M(+6082.7%)
Sep 2004
-
$132.50 K(-5.6%)
Jun 2004
-
$140.40 K(-35.3%)
Mar 2004
-
$217.10 K(-62.9%)
Dec 2003
$585.10 K(-50.0%)
$585.10 K(+102.6%)
Sep 2003
-
$288.80 K(-42.0%)
Jun 2003
-
$497.90 K(-27.4%)
Mar 2003
-
$685.90 K(-41.4%)
Dec 2002
$1.17 M(-40.0%)
$1.17 M(-19.0%)
Sep 2002
-
$1.44 M(-9.1%)
Jun 2002
-
$1.59 M(-10.6%)
Mar 2002
-
$1.78 M(-8.8%)
Dec 2001
$1.95 M(-12.7%)
$1.95 M(+20.1%)
Sep 2001
-
$1.62 M(-11.1%)
Jun 2001
-
$1.83 M(-10.0%)
Mar 2001
-
$2.03 M(-9.1%)
Dec 2000
$2.23 M(-48.2%)
$2.23 M(-8.3%)
Sep 2000
-
$2.44 M(-9.1%)
Jun 2000
-
$2.68 M(-6.1%)
Mar 2000
-
$2.86 M(+2755.3%)
Dec 1999
$4.31 M(+2669.1%)
-
Jun 1999
-
$100.00 K(0.0%)
Mar 1999
-
$100.00 K(-35.8%)
Dec 1998
$155.80 K(-92.5%)
$155.80 K(-96.7%)
Sep 1998
-
$4.70 M(+2.2%)
Jun 1998
-
$4.60 M(+4.5%)
Mar 1998
-
$4.40 M(+112.7%)
Dec 1997
$2.07 M(+106.9%)
$2.07 M(+3.4%)
Sep 1997
-
$2.00 M(+5.3%)
Jun 1997
-
$1.90 M(+46.2%)
Mar 1997
-
$1.30 M(+30.0%)
Dec 1996
$1.00 M(-9.1%)
$1.00 M(0.0%)
Sep 1996
-
$1.00 M(+66.7%)
Jun 1996
-
$600.00 K(0.0%)
Mar 1996
-
$600.00 K(-45.5%)
Dec 1995
$1.10 M(-8.3%)
$1.10 M(-8.3%)
Sep 1995
-
$1.20 M(+500.0%)
Jun 1995
-
$200.00 K(0.0%)
Mar 1995
-
$200.00 K(-83.3%)
Dec 1994
$1.20 M(+1100.0%)
$1.20 M(+200.0%)
Sep 1994
-
$400.00 K(0.0%)
Jun 1994
-
$400.00 K(+100.0%)
Mar 1994
-
$200.00 K(+100.0%)
Dec 1993
$100.00 K
$100.00 K(0.0%)
Sep 1993
-
$100.00 K

FAQ

  • What is Navidea Biopharmaceuticals annual total long term liabilities?
  • What is the all time high annual total long term liabilities for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals annual total long term liabilities year-on-year change?
  • What is Navidea Biopharmaceuticals quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals quarterly long term liabilities year-on-year change?

What is Navidea Biopharmaceuticals annual total long term liabilities?

The current annual total long term liabilities of NAVB is $2.57 M

What is the all time high annual total long term liabilities for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high annual total long term liabilities is $62.62 M

What is Navidea Biopharmaceuticals annual total long term liabilities year-on-year change?

Over the past year, NAVB annual total long term liabilities has changed by +$1.85 M (+257.21%)

What is Navidea Biopharmaceuticals quarterly total long term liabilities?

The current quarterly long term liabilities of NAVB is $700.30 K

What is the all time high quarterly long term liabilities for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high quarterly total long term liabilities is $63.07 M

What is Navidea Biopharmaceuticals quarterly long term liabilities year-on-year change?

Over the past year, NAVB quarterly total long term liabilities has changed by -$200.00 (-0.03%)